Pharmacogenomics in psychiatry is the field where genetic testing informs prescribing decisions. The evidence base has matured for specific applications and remains debated for others. Knowing where pharmacogenomics is genuinely useful versus where the marketing exceeds the evidence is part of modern psychiatric practice.
- Class
- Pharmacogenomic testing framework
- Mechanism
- Genetic variation in drug-metabolizing enzymes (CYP2D6, CYP2C19, others) and HLA alleles produces individual differences in drug exposure, response, and adverse effect risk
- FDA indications
- Optimizing antidepressant/antipsychotic selection, screening before specific medications (carbamazepine in Asians), explaining inadequate response or adverse effects
- Representative agents
- CYP2D6 (variable activity for many antidepressants, antipsychotics, atomoxetine), CYP2C19 (citalopram, escitalopram, several PPIs), HLA-B*1502 (carbamazepine, lamotrigine — Asian populations), HLA-B*5701 (abacavir — non-psychiatric example)
Selective use: HLA-B*1502 before carbamazepine in Asian patients is established. Routine pharmacogenomic testing for all psychiatric medications is debated — evidence of meaningful clinical improvement over standard care is mixed. Useful in specific situations: multiple failed antidepressant trials, unusual adverse effect patterns, planned use of medications with strong genotype-phenotype correlations.
Established applications: HLA-B*1502 testing before carbamazepine in patients of Asian ancestry. The allele substantially elevates risk of Stevens-Johnson syndrome and toxic epidermal necrolysis with carbamazepine. The FDA recommends testing in patients of Han Chinese, Thai, Filipino, and related ancestry before initiating carbamazepine. Positive result means use an alternative agent. This is one of the cleanest pharmacogenomic interventions in clinical medicine.
CYP variability is the broader pharmacogenomic landscape. CYP2D6 metabolizes many psychiatric drugs (most SSRIs, several antipsychotics, atomoxetine, codeine, tamoxifen). Poor metabolizers (~5-10% Caucasians) have higher exposures and more side effects from 2D6 substrates. Ultra-rapid metabolizers (~3-5%) have lower exposures and reduced efficacy. CYP2C19 affects metabolism of escitalopram, citalopram, and several PPIs. Testing reveals genotype; clinical practice translates genotype into dose adjustments or agent choices.
Pharmacogenomics in psychiatry is most useful where genotype predicts drug exposure — the pharmacokinetic variants are more clinically actionable than the pharmacodynamic ones.
Mechanism note: Pharmacogenomics is most actionable for pharmacokinetic variants (CYP2D6/2C19) and HLA-B*1502 — the pharmacodynamic 'response prediction' panels run well ahead of their evidence.
When pharmacogenomic testing helps clinically: Multiple failed antidepressant trials with unclear reasons. Unusual reactions to a drug suggesting altered metabolism. Patient with strong family history of severe medication reactions. Planned use of medications with strong genotype-phenotype correlations (carbamazepine in Asian patients).
When the evidence is weaker: Routine universal pharmacogenomic testing in all psychiatric patients. The actionable genes are limited, the clinical-outcome data are mixed, and insurance coverage is variable. The commercial pharmacogenomic panels often produce results of limited practical impact on prescribing decisions.
Targeted application — HLA-B*1502, specific clinical questions in patients with unusual response patterns — is evidence-supported. Universal testing for routine antidepressant choice is not. Use pharmacogenomics where it actually changes management.